Skip to content
Markets News
Stocks1 min read

EU Clears Enhertu for Some Early Breast Cancer Patients

Makkler Newsroom
October 27, 2026 · Based on reporting by finanzen.net

AstraZeneca and Daiichi Sankyo said the EU approved Enhertu as a single treatment after surgery for patients with residual HER2-positive disease.

Key takeaways

  • The EU approved Enhertu as a monotherapy for certain patients with early HER2-positive breast cancer.
  • The companies said this is the drug’s first EU approval for early breast cancer with curative intent.

The European Commission has approved AstraZeneca and Daiichi Sankyo’s Enhertu for certain patients with early-stage HER2-positive breast cancer. The treatment is for patients who have residual disease after surgery and will be used as a monotherapy.

The companies said the EU approval followed a recommendation from the European Medicines Agency’s scientific committee. They described it as Enhertu’s first EU approval for early breast cancer with curative intent.

The decision was based on late-stage clinical trial data that showed the drug reduced the risk of disease recurrence or death, according to the companies.

AstraZeneca shares traded at 12,822 GBp on Tuesday afternoon, down 0.25% since the previous close.

Topics
AZN4568Enhertu
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.